At this stage in the negotiation process, we believe decisions are being made not only on dollars and cents, but also ego, strategy and a broader view of the competitive landscape.
I suspect that Johnson & Johnson will be in the market sooner rather than later.
I think J&J has a claim. I don't think they are going to have to pay Guidant.
In our opinion this news is not new and should not slow down the merger with Guidant.
Interestingly, (Boston Scientific) only raised its bid by $1, signaling that price is but one factor in the negotiation - but includes timeliness of closure.
The good news is that this is not a recall, products are not being removed from hospital shelves, and no one has died.
There's a phrase: to strike while the iron is hot. The iron is hot.
They are playing chicken, and right now it appears that J&J has the upper hand.
They're certainly making it harder for J&J to come back. Strategically we believe Boston Scientific with Guidant is a better match.
We doubt this show is over, and in the end we expect that Boston Scientific will increase its bid.
You know where you stand with him. Nothing is candy-coated.
This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.
This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.